Work

Supplemental Material from A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Table 1 (Patient Incidence of Treatment-Related Adverse Events) and Supplemental Figure 1 (AMG 780 dose cohorts and patient enrollment)

DOI: 10.1158/1078-0432.22455260

Authors: Afshin Dowlati, Gordana Vlahovic, Ronald B. Natale, Erik Rasmussen, Indrajeet Singh, Yuying C. Hwang, John Rossi, Michael B. Bass, Gregory Friberg, Cheryl A. Pickett

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361883790

Cites:

Cited by:

Related to: 10